75 results about "SKIN BENIGN NEOPLASM" patented technology

Methods, compositions and products for preventing skin tumor formation or inhibiting development of an existing skin tumor in a subject are described. The methods involve administering to the subject a composition containing an α2 adrenergic receptor agonist, such brimonidine.

Compositions of human proteins, methods and regimens for reducing the occurrence and growth of skin cancer, including melanoma, are provided. The methods include steps of administering topically on the skin tumor or a skin cancer-free area of compositions containing therapeutically effective amounts of human alkaline phosphatase, transferrin and α1-antitrypsin. In some embodiments, the composition is topically administered and includes all three proteins. Alkaline phosphatase, alone or in combination with transferrin and α1-antitrypsin can also be administered by injection with or without simultaneous or sequential topical administration. Administration of compositions topically and / or by injection can be part of a more complex cancer therapy including chemotherapy, radiotherapy, surgery, and electrochemotherapy.

Embodiments of the invention relate to a method of treating a cancerous or non-cancerous skin lesion of a subject, e.g. a human patient, by epidermal radioisotope therapy, a specialized type of brachytherapy. The method can include defining and marking an area of skin to be treated; covering the area with a protective layer, e.g. a protective film or foil; applying a tailor-made radioactive source by applying a layer of a radioactive source material on the protective layer, such that the area is covered by the material while any area not to be treated is spared; and removing the radioactive source after a predetermined time period of irradiation.

The present invention relates to the effect of naturally occurring compounds on tumor development. As an example of proof, we used low; non-toxic doses of three compound e.g. Calcium D-glucarate, a naturally occurring Ca++ salt of D-glucaric acid; Nicotinamide (NA), a naturally occurring vitamin and butyric acid (BA), a naturally occurring saturated short chain fatty acid. 7,12 dimethylbenzanthracene (DMBA), which is a very potent skin carcinogen and is an environmental pollutant, was used for skin tumor development. Experiment was performed up to 30 weeks. All the above-mentioned compounds were used either alone or concomitantly any two or all the three. In the positive control group 100% tumorigenesis was attained in 28 weeks, use of single compound led to the inhibition of DMBA induced tumorigenesis between 33 to 47%, use of two compounds resulted in the 73 to 80% reduction in tumorigenesis but the concomitant use of three compounds resulted into 100% inhibition of tumor development at the end of 30 weeks. This led us to conclude that the concomitant use of Cag, NA and BA in combination of two is useful for preventing skin tumor development for a sort or long period of time. But the concomitant use of all the three compounds, as described, exhibited the perfect synergistic effect in preventing the tumor development completely. This strategy should be equally effective in the management of benign and possibly malignant tumor in any organ caused by any mean.

Methods, compositions and products for preventing skin tumor formation or inhibiting the development of an existing skin tumor in a subject are described. The methods involve administering to the subject a composition containing an α2 adrenergic receptor agonist, such as brimonidine.

The invention relates to a grading model for detecting benign and malignant degrees of skin tumors and application thereof. According to the model, changes of imprinting genes in tumors are graded bycalculating imprinting gene deletion expression quantity, imprinting gene copy number abnormal expression quantity and imprinting gene total expression quantity. According to the detection model and the device provided by the invention, the expression of the imprint deletion on the tissue and the cell sample of a skin tumor patient is represented by using the intuitive method, the imprint (trace)gene change is objectively, intuitively, early and accurately detected through adoption of an imprint gene in-situ labeling method, the quantitative model can be provided, and the great contribution is provided for the diagnosis of the skin tumor.

Compounds of following general formula (I) and pharmaceutical compositions thereof for inhibiting mammalian tumor cell proliferation are disclosed. In formula (I), n is an integer from 0 to 9. The cell proliferation of breast tumor, ovarian tumor, skin tumor or liver tumor is inhibited by the compounds of the formula (I).